Xeris Biopharma Holdings (XERS)

• Market cap: $517M
• 1 day: 1.46%
• 5 days: 1.17%
• 1 month: 12.66%
• 3 months: 23.05%
• 6 months: 64.45%
• Year to date: 52.86%
• 1 year: 55.61%
• 5 years: -56.68%
• 10 years: -82.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Employees: 377

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

271% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $340K

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

30% more capital invested

Capital invested by funds: $140M [Q2] → $182M (+$41.7M) [Q3]

29% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 35

5% more funds holding

Funds holding: 134 [Q2] → 141 (+7) [Q3]

0.81% more ownership

Funds ownership: 42.02% [Q2] → 42.83% (+0.81%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 14% downside
• Avg. target: $4.80 38% upside
• High target: $6.60 90% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	90% upside $6.60	Buy Maintained	11 Nov 2024
Piper Sandler David Amsellem 46% 1-year accuracy 17 / 37 met price target	14% downside $3	Neutral Downgraded	11 Nov 2024